elder law weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of elder law weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arcturus Bioscience, Inc.
Gene expression ratio identifies recurrence risk in patients receiving tamoxifen
June 23rd, 2004
A simple measurement of the expression levels of two genes in breast cancer tissue appears to identify tumors that are more likely to recur in women treated with tamoxifen for early-stage disease. Determining patients for whom tamoxifen treatment is likely to fail would allow earlier use of other therapies that could be more effective for those women. Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Arcturus Bioscience, Inc., described their findings in the June 2004 issue of Cancer Cell. The paper was released online on June 3, 2004, (www.cancercell.org) and related material was presented at the June 5-8, 2004,...
Source: elder law weekly (2004-06-23)
|
